Adapting to uncertainty over product review timelines at FDA could complicate M&A for pharma buyers and sellers, especially ...

Improvements in diagnostics for the early detection of Alzheimer's disease have the potential to transform patient care and ...

For small pharmas and biotechs approaching a commercial launch, agility and execution are more valuable than waiting for a ...

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning ...

FUJIFILM Diosynth Biotechnologies, a leading global contract development and manufacturing organization (CDMO) with a significant presence in North Carolina, has entered into a landmark agreement with ...

The GLP-1 drug market is booming, fueled by their success in treating diabetes and obesity. Yet, this growth has unleashed a torrent of litigation — patent disputes, regulatory battles, and clashes ...

The traditional boundaries between consumer wellness and healthcare are rapidly dissolving. This convergence is creating unprecedented opportunities for innovation, while fundamentally changing how ...

Creating and bringing new medicines to patients is a uniquely complicated process. It requires robust scientific research, business acumen, tremendous financial investment, and patience — even when ...

In most life sciences companies, commercial teams are pulled into BD conversations, but often the depth of evaluation falls short of making real impact. By the time we’re asked to weigh in, key ...